Literature DB >> 25443643

Sidestream dark field videomicroscopy for in vivo evaluation of vascularization and perfusion of mammary tumours in HER2/neu transgenic mice.

Elisa Damiani1, Elisa Pierpaoli, Fiorenza Orlando, Abele Donati, Mauro Provinciali.   

Abstract

Angiogenesis plays a key role in tumour growth and the formation of metastases. Angiogenesis inhibitors and antivascular agents may prove useful in the treatment of breast cancer. A comprehensive characterization of the vasculature and perfusion of mammary tumours is a prerequisite for developing new specific drugs. We used sidestream dark field videomicroscopy to evaluate in vivo the vascular network of spontaneous mammary tumours in HER2/neu transgenic mice. The tumour masses showed higher vessel density compared with the healthy mammary gland (median (interquartile range) total vessel density 16.8 (13.4-20.5) vs 9.1 (8.1-10.9) mm/mm(2), respectively; P < 0.001). Tumor vessel density was reduced in mice treated with the anti-angiogenesis agent berberine, 12.1 (10.6-13.1) mm/mm(2). Sidestream dark field imaging is a versatile technique that may be useful for understanding the role of angiogenesis in the progression of breast cancer and its relationship with outcome. It may represent a valuable tool for dynamic monitoring of the effects of new anti-angiogenesis therapies.
© 2014 Wiley Publishing Asia Pty Ltd.

Entities:  

Keywords:  angiogenesis; breast cancer; sidestream dark field videomicroscopy

Mesh:

Substances:

Year:  2015        PMID: 25443643     DOI: 10.1111/1440-1681.12343

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  1 in total

1.  Effects of the Infusion of 4% or 20% Human Serum Albumin on the Skeletal Muscle Microcirculation in Endotoxemic Rats.

Authors:  Elisa Damiani; Can Ince; Fiorenza Orlando; Elisa Pierpaoli; Oscar Cirioni; Andrea Giacometti; Federico Mocchegiani; Paolo Pelaia; Mauro Provinciali; Abele Donati
Journal:  PLoS One       Date:  2016-03-04       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.